Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, discusses what clinicians need to be conscious about regarding the outcomes disparities between adolescents and young adults with acute lymphoblastic leukemia (ALL), and children with ALL.
Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, discusses what clinicians need to be conscious about regarding the outcomes disparities between adolescents and young adults with acute lymphoblastic leukemia (ALL), and children with ALL.
Transcript
In what ways can clinicians be conscious of the outcomes disparities between adolescents and young adults with ALL, and children with ALL?
That’s a really good question. There’s a lot of things that impact this. This is just the tip of the iceberg. We’re going to move forward and really try to figure this out but I think the first thing that clinicians can do is just to be aware that these patients are different from children and they’re different from patients that are over 40 as well. They’re different from their older adults that walk through the door and that really there’s a lot of different things that need to be considered in terms of treatment on a clinical trial and consideration of what kind of treatment they give them.
So really what I think in terms of thinking about these patients, the most important thing is for clinicians to recognize that they’re different from their younger counterparts and from their older counterparts. So when someone walks through your door and and they’re diagnosed with ALL and they’re under 40, I think the most important thing is to think about them as a unique group. Think about the kind of treatment they receive, and really, because of this duration of treatment, think about the kind of treatment you’re giving, and really, keeping them on track and making sure that they finish and don’t fall off at the end, which happens. These patients, sometimes because of all of the psycho-social stressors in their lives, they’re at this very unique time in their lives and there’s so much going on and so they do need psycho-social support in different ways. We haven’t shown this specifically and we really need to take that all into account, though.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More